Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21981810 | 0.84 | ADORA2A (0.33) | BACE1 | |
| SCHEMBL9899507 | 0.82 | BACE1 (0.35) | CYP19A1BACE1 | |
| SCHEMBL9899510 | 0.82 | BACE1 (0.35) | CYP19A1BACE1 | |
| SCHEMBL21981909 | 0.82 | BACE1 (0.39) | CYP19A1BACE1OPRM1 | |
| SCHEMBL21981931 | 0.81 | — | — | |
| SCHEMBL21981794 | 0.81 | BACE1 (0.31) | CYP19A1BACE1 | |
| SCHEMBL28603634 | 0.80 | CYP19A1 (0.41) | CYP19A1BACE1 | |
| SCHEMBL21981754 | 0.79 | — | — | |
| SCHEMBL2595 | 0.78 | BACE1 (0.36) | BACE1 | |
| SCHEMBL2594 | 0.78 | BACE1 (0.36) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | UCB Biopharma SRL (BE) | 2021-10-05 | — | — | US | disclosed |
| US-20200283416-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | CELLTECH R&D LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| EP-3380464-B1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB Biopharma SRL (BE) | 2020-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283416-A1 | IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS | PEPD, ADAM17, ANPEP | CYP19A1 2963/4885BACE1 608/4885OPRM1 2884/4885 |
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | PEPD, ADAM17, ANPEP | CYP19A1 2963/4885BACE1 608/4885OPRM1 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.